- Home
- ZURA vs EPIX Comparison
ZURA vs EPIX Comparison
Compare ZURA & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- EPIX
- Stock Information
- Founded
- ZURA 2022
- EPIX 2009
- Country
- ZURA United States
- EPIX Canada
- Employees
- ZURA N/A
- EPIX N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- ZURA Health Care
- EPIX Health Care
- Exchange
- ZURA Nasdaq
- EPIX Nasdaq
- Market Cap
- ZURA 69.9M
- EPIX 75.9M
- IPO Year
- ZURA N/A
- EPIX N/A
- Fundamental
- Price
- ZURA $1.31
- EPIX $1.72
- Analyst Decision
- ZURA Buy
- EPIX Hold
- Analyst Count
- ZURA 7
- EPIX 3
- Target Price
- ZURA $14.33
- EPIX $2.00
- AVG Volume (30 Days)
- ZURA 708.2K
- EPIX 53.1K
- Earning Date
- ZURA 08-08-2025
- EPIX 08-04-2025
- Dividend Yield
- ZURA N/A
- EPIX N/A
- EPS Growth
- ZURA N/A
- EPIX N/A
- EPS
- ZURA N/A
- EPIX N/A
- Revenue
- ZURA N/A
- EPIX N/A
- Revenue This Year
- ZURA N/A
- EPIX N/A
- Revenue Next Year
- ZURA N/A
- EPIX N/A
- P/E Ratio
- ZURA N/A
- EPIX N/A
- Revenue Growth
- ZURA N/A
- EPIX N/A
- 52 Week Low
- ZURA $0.97
- EPIX $1.40
- 52 Week High
- ZURA $5.07
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- ZURA 59.63
- EPIX 51.31
- Support Level
- ZURA $1.00
- EPIX $1.68
- Resistance Level
- ZURA $1.45
- EPIX $1.75
- Average True Range (ATR)
- ZURA 0.10
- EPIX 0.04
- MACD
- ZURA 0.03
- EPIX 0.00
- Stochastic Oscillator
- ZURA 68.89
- EPIX 62.50
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.